Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $22,008 | 9 | 94.2% |
| Travel and Lodging | $1,299 | 5 | 5.6% |
| Food and Beverage | $47.99 | 4 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19,354 | 17 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $4,000 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,628 | 1 | Merck Sharp & Dohme LLC ($1,628) |
| 2019 | $7,184 | 5 | Merck Sharp & Dohme Corporation ($7,184) |
| 2018 | $5,124 | 6 | Merck Sharp & Dohme Corporation ($5,124) |
| 2017 | $9,418 | 6 | Merck Sharp & Dohme Corporation ($5,418) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/04/2023 | Merck Sharp & Dohme LLC | NOXAFIL (Drug) | Consulting Fee | Cash or cash equivalent | $1,627.50 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/18/2019 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/25/2019 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Consulting Fee | Cash or cash equivalent | $6,375.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/25/2019 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Travel and Lodging | Cash or cash equivalent | $107.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/04/2019 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Travel and Lodging | In-kind items and services | $261.64 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/04/2019 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/21/2018 | Merck Sharp & Dohme Corporation | MK-7655A (Drug) | Consulting Fee | Cash or cash equivalent | $3,340.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/21/2018 | Merck Sharp & Dohme Corporation | MK-7655A (Drug) | Travel and Lodging | Cash or cash equivalent | $42.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/14/2018 | Merck Sharp & Dohme Corporation | MK-7655A (Drug) | Travel and Lodging | In-kind items and services | $424.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/14/2018 | Merck Sharp & Dohme Corporation | MK-7655A (Drug) | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/14/2018 | Merck Sharp & Dohme Corporation | MK-7655A (Drug) | Food and Beverage | In-kind items and services | $4.91 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/12/2018 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/08/2017 | Bayer HealthCare Pharmaceuticals Inc. | Cipro (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: Other | ||||||
| 08/08/2017 | Merck Sharp & Dohme Corporation | MK-7655A (Drug) | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/26/2017 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug) | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/30/2017 | Merck Sharp & Dohme Corporation | MK-7655A (Drug) | Travel and Lodging | In-kind items and services | $463.07 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/30/2017 | Merck Sharp & Dohme Corporation | MK-7655A (Drug) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/16/2017 | Merck Sharp & Dohme Corporation | MK-7655A (Drug) | Consulting Fee | Cash or cash equivalent | $520.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 36 | 39 | $10,300 | $4,110 |
| 2021 | 3 | 63 | 72 | $17,965 | $7,357 |
| 2020 | 4 | 102 | 129 | $26,770 | $10,901 |
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $4,400 | $1,776 | 40.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $3,660 | $1,368 | 37.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 13 | 16 | $2,240 | $965.22 | 43.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $6,800 | $2,839 | 41.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 21 | 21 | $6,405 | $2,436 | 38.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 25 | 34 | $4,760 | $2,081 | 43.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 40 | 40 | $12,190 | $4,727 | 38.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 36 | 58 | $8,160 | $3,608 | 44.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $4,800 | $1,919 | 40.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 14 | 19 | $1,620 | $646.61 | 39.9% |
About Dr. Thomas Fekete, MD
Dr. Thomas Fekete, MD is a Infectious Disease healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1134116056.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Fekete, MD has received a total of $23,354 in payments from pharmaceutical and medical device companies, with $1,628 received in 2023. These payments were reported across 18 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($22,008).
As a Medicare-enrolled provider, Fekete has provided services to 201 Medicare beneficiaries, totaling 240 services with total Medicare billing of $22,367. Data is available for 3 years (2020–2022), covering 10 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Philadelphia, PA
- Active Since 10/05/2005
- Last Updated 04/20/2018
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1134116056
Products in Payments
- MK-7655A (Drug) $8,072
- RECARBRIO (Drug) $7,184
- NOXAFIL (Drug) $4,098
- Cipro (Drug) $4,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Philadelphia
Judith Wolf, Md, MD
Infectious Disease — Payments: $1.4M
Karam Mounzer, Md, MD
Infectious Disease — Payments: $802,727
William Short, Md, MD
Infectious Disease — Payments: $514,722
Pablo Tebas, Md, MD
Infectious Disease — Payments: $227,362
Ian Frank, Md, MD
Infectious Disease — Payments: $152,592
Lisa Spacek, M.d, M.D
Infectious Disease — Payments: $100,519